• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CalAmp Corp. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    1/26/24 9:01:32 AM ET
    $CAMP
    Get the next $CAMP alert in real time by email
    8-K
    0000730255false--02-2800007302552024-01-252024-01-25

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): January 25, 2024

     

     

    CalAmp Corp.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    0-12182

    95-3647070

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    15635 Alton Parkway

    Suite 250

     

    Irvine, California

     

    92618

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (949) 600-5600

     

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common stock, $0.01 per share

     

    CAMP

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 3.03. Material Modification to Rights of Security Holders

    On January 25, 2024, the Board of Directors (the “Board”) of CalAmp Corp., a Delaware corporation (the “Company”) approved a reverse stock split of the Company’s issued and outstanding shares of common stock, $0.01 par value per share (the “Common Stock”), at a ratio of 1-for-23 (the “Reverse Stock Split”). The Reverse Stock Split will be effective as of 5:00 p.m. eastern time on February 1, 2024 (the “Effective Date”).

    Reason for the Reverse Stock Split

    The Company is effecting the Reverse Stock Split to satisfy the $1.00 minimum bid price requirement, as set forth in Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”), for continued listing on the Nasdaq Stock Market LLC (“Nasdaq”) exchange. As previously disclosed on August 23, 2023, the Company received a letter from Nasdaq on August 22, 2023, indicating that for the then last thirty (30) consecutive business days, the Company was not in compliance with the Minimum Bid Requirement.

    In accordance with Listing Rule 5810(c)(3)(A), the Company has been granted one-hundred eighty (180) calendar days, or until February 18, 2024, to regain compliance with the Minimum Bid Requirement (the “Compliance Period”). To regain compliance, the closing bid price of the Company’s Common Stock must be at least $1.00 per share for a minimum of ten (10) consecutive business during the Compliance Period.

    Effects of the Reverse Stock Split

    Effective Date; Symbol; CUSIP Number. The Reverse Stock Split becomes effective with Nasdaq and the Common Stock will begin trading on a split-adjusted basis at the open of business on the day following the Effective Date. In connection with the Reverse Stock Split, the CUSIP number for the Common Stock will change to 128126208. The trading symbol for the Company, CAMP, will not be changed.

    Split Adjustment; Treatment of Fractional Shares. On the Effective Date, the total number of shares of Common Stock held by each stockholder of the Company will be converted automatically into (i) the number of issued and outstanding shares of Common Stock held by each such stockholder immediately prior to the Reverse Stock Split divided by (ii) 23. Any fractional share of Common Stock that would otherwise result from the Reverse Stock Split will be rounded up to the nearest whole share and, as such, any stockholder who otherwise would have held a fractional share after giving effect to the Reverse Stock Split will instead hold one whole share of the post-Reverse Stock Split Common Stock after giving effect to the Reverse Stock Split. As a result, no fractional shares will be issued in connection with the Reverse Stock Split and no cash or other consideration will be paid in connection with any fractional shares that would otherwise have resulted from the Reverse Stock Split. The Company intends to treat stockholders holding shares of Common Stock in “street name” (that is, held through a bank, broker or other nominee) in the same manner as stockholders of record whose shares of Common Stock are registered in their names. Banks, brokers or other nominees will be instructed to effect the Reverse Stock Split for their beneficial holders holding shares of our Common Stock in “street name;” however, these banks, brokers or other nominees may apply their own specific procedures for processing the Reverse Stock Split.

    Also on the Effective Date, all options, warrants and other convertible securities of the Company outstanding immediately prior to the Reverse Stock Split will be adjusted by dividing the number of shares of Common Stock into which the options, warrants and other convertible securities are exercisable or convertible by 23 and multiplying the exercise or conversion price thereof by 23, all in accordance with the terms of the plans, agreements or arrangements governing such options, warrants and other convertible securities and subject to rounding to the nearest whole share. Such proportional adjustments will also be made to the number of shares and restricted stock units issued and issuable under the Company’s equity compensation plan.

    Certificated and Non-Certificated Shares. Stockholders who are holding their shares in electronic form at brokerage firms do not need to take any action, as the effect of the Reverse Stock Split will automatically be reflected in their brokerage accounts.

    After the Reverse Stock Split becomes effective, the Company’s transfer agent and registrar, Equiniti Trust Company, LLC (formerly known as American Stock Transfer & Trust Company, LLC) (“Equiniti”) will mail instructions for submitting paper certificates in exchange for new certificates reflecting the Reverse Stock Split. Equiniti can be contacted at (718) 921-8288, but stockholders should not submit their paper certificates until they receive and complete the instructions for transmittal which Equiniti will mail to them.

    Certificate of Amendment. The Company will effect the Reverse Stock Split pursuant to the Company’s filing of a certificate of amendment of the Company’s amended and restated certificate of incorporation (the “Certificate”) with the Delaware Secretary of State effective at 5:00 p.m. eastern time on January 25, 2024, in accordance with Delaware Law. A copy of the Certificate is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

    Stockholder Approval. At the Company’s Special Meeting held on January 25, 2024, the stockholders approved a proposal to grant the Board of Directors discretion to implement a reverse stock split in a range of one-for-ten up to one-for-fifty. As such the Reverse Stock Split was approved in accordance with Delaware law.

    Capitalization. As of January 24, 2024, there were 37,969,389 shares of Common Stock outstanding. As a result of the Reverse Stock Split, there will be approximately 1,650,843 shares of Common Stock outstanding (subject to adjustment due to the effect of rounding fractional shares into whole shares). The Reverse Stock Split will not have any effect on the stated par value of the Common Stock. The Total number of the Company’s authorized shares of Common Stock shall not be affected by the foregoing.


    Immediately after the Reverse Stock Split, each stockholder’s relative ownership in the interest in the Company and proportional voting power will remain virtually unchanged except for minor changes and adjustments that will result from rounding fractional shares into whole shares.


    Item 5.03. Amendments to Articles of Incorporation or Bylaws

    The information set forth in Item 3.03 of this Current Report on Form 8-K with respect to the Company’s amended and restated certificate of incorporation effecting the Reverse Stock Split is incorporated by reference into Item 5.03 of this Current Report on Form 8-K.


    Item 5.07 Submission of Matters to a Vote of Security Holders

     

    A special meeting of stockholders (the “Special Meeting”) of the Company was held on January 25, 2024. 27,757,130 shares of the Company’s Common Stock (including shares represented by proxy) were present at the Special Meeting, representing approximately 73.06% of the shares of the Common Stock outstanding as of November 30, 2023, the record date for the Special Meeting, and a quorum.

    Matters submitted to the stockholders and voted upon at the Special Meeting, which are more fully described in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on December 12, 2023, were (i) to authorize the Board to amend the Company’s Amended and Restated Certificate of Incorporation to effect the Reverse Stock Split of the Company’s outstanding shares of Common Stock at a reverse stock split ratio in the range of one-for-ten through one-for-fifty (the “Reverse Stock Split Proposal”), and (ii) to approve the postponement or adjournment of the Special Meeting if necessary or appropriate, to permit further solicitation and vote of proxies if there were insufficient votes to approve the Reverse Stock Split Proposal (the “Adjournment Proposal”).

    At the Special Meeting, the Company’s stockholders approved the two proposals. The final results were as follows:

    (1)
    Approval of the Reverse Stock Split Proposal by the stockholders of the Company, voting as a single class:

    For

    Against

    Abstain

    25,240,754

    2,490,754

    25,622

    (2)
    Approval of the Adjournment Proposal by the stockholders of the Company, voting as a single class:

    For

    Against

    Abstain

    25,175,826

    2,535,765

    45,539

     


    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    3.1

    Second Certificate of Amendment of the Amended and Restated Certificate of Incorporation of CalAmp Corp.

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    CALAMP CORP.

     

     

     

     

    Date:

    January 25, 2024

    By:

    /s/ Jikun Kim

     

     

     

    Jikun Kim
    Senior Vice President and CFO
    (Principal Financial Officer)

     


    Get the next $CAMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAMP

    DatePrice TargetRatingAnalyst
    10/2/2025$7.00Overweight
    Cantor Fitzgerald
    9/16/2025Overweight → Neutral
    Analyst
    5/27/2025$8.00Outperform
    Wedbush
    11/5/2024Outperform
    William Blair
    11/5/2024$18.00Overweight
    Piper Sandler
    11/5/2024$23.00Overweight
    JP Morgan
    8/16/2022$8.00 → $10.00Hold → Buy
    Craig Hallum
    12/22/2021$15.00 → $14.00Buy
    Canaccord Genuity
    More analyst ratings

    $CAMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Scientific Officer Tardiff Daniel

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    12/22/25 5:42:07 PM ET
    $CAMP

    SEC Form 4 filed by Chief Medical Officer Maricich Yuri

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    12/22/25 5:41:49 PM ET
    $CAMP

    SEC Form 4 filed by Chief Financial Officer Gold Kelly

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    12/22/25 5:41:33 PM ET
    $CAMP

    $CAMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on CAMP4 Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $7.00

    10/2/25 8:38:59 AM ET
    $CAMP

    CAMP4 Therapeutics downgraded by Analyst

    Analyst downgraded CAMP4 Therapeutics from Overweight to Neutral

    9/16/25 8:02:50 AM ET
    $CAMP

    Wedbush initiated coverage on CAMP4 Therapeutics with a new price target

    Wedbush initiated coverage of CAMP4 Therapeutics with a rating of Outperform and set a new price target of $8.00

    5/27/25 9:09:57 AM ET
    $CAMP

    $CAMP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on February 16, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the

    2/20/26 4:05:00 PM ET
    $CAMP

    CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on January 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the C

    1/16/26 4:05:00 PM ET
    $CAMP

    CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 14, 2026, at 3:45 p.m. PST. The event will be webcast and can be accessed on the investor relations page of CAMP4's website at

    1/6/26 8:00:00 AM ET
    $CAMP

    $CAMP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner 5am Partners Vi, Llc bought $4,499,999 worth of shares (2,941,176 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/15/25 8:12:20 PM ET
    $CAMP

    Large owner Polaris Management Co. Vii, L.L.C. bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/11/25 4:59:09 PM ET
    $CAMP

    Director Nashat Amir bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/11/25 4:48:30 PM ET
    $CAMP

    $CAMP
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by CAMP4 Therapeutics Corporation

    SCHEDULE 13G/A - Camp4 Therapeutics Corp (0001736730) (Subject)

    2/5/26 1:20:38 PM ET
    $CAMP

    CAMP4 Therapeutics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

    1/9/26 4:32:35 PM ET
    $CAMP

    SEC Form SCHEDULE 13G filed by CAMP4 Therapeutics Corporation

    SCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

    1/8/26 12:15:25 PM ET
    $CAMP

    $CAMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

    SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 6:49:57 PM ET
    $CAMP

    SEC Form SC 13D filed by CAMP4 Therapeutics Corporation

    SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 5:50:56 PM ET
    $CAMP

    SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

    SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

    10/22/24 4:19:08 PM ET
    $CAMP

    $CAMP
    Financials

    Live finance-specific insights

    View All

    CalAmp Reports Third Quarter Fiscal Year 2024 Financial Results

    IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview    Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5

    1/9/24 4:30:00 PM ET
    $CAMP

    CalAmp Announces Date for Fiscal 2024 Third Quarter Earnings Conference Call

    IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla

    12/26/23 4:30:00 PM ET
    $CAMP

    CalAmp Announces Completion of Strategic Financing with Lynrock Lake

    IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add

    12/18/23 4:31:00 PM ET
    $CAMP

    $CAMP
    Leadership Updates

    Live Leadership Updates

    View All

    Sequans Appoints Jason W. Cohenour to Board of Directors

    Paris, France--(Newsfile Corp. - June 30, 2025) - Sequans Communications S.A. (NYSE:SQNS), a leading innovator in cellular IoT semiconductor solutions, today announced the appointment of Jason W. Cohenour to its Board of Directors.Mr. Cohenour brings more than 30 years of executive leadership experience across sales, operations, and international mergers and acquisitions. He served as President, CEO, and Director of Sierra Wireless, Inc. (TSX:SW) (NASDAQ:SWIR) from 2005 to 2018, where he led a strategic transformation that created a global leader in the Internet of Things and drove company revenues to nearly USD $800 million. Prior to his CEO role, he held several senior positions at Sierra

    6/30/25 8:00:00 AM ET
    $CAMP
    $LTRX
    $RFIL
    Computer Communications Equipment
    Telecommunications
    Electrical Products
    Technology

    CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

    With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company's Board of Directors. "We are delighted to welcome Drs. William

    3/18/25 8:00:00 AM ET
    $CAMP

    CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

    CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

    12/10/24 8:00:00 AM ET
    $CAMP
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care